• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Avanos Medical Inc.

    2/10/23 2:34:49 PM ET
    $AVNS
    Industrial Specialties
    Health Care
    Get the next $AVNS alert in real time by email
    SC 13G 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. _ )*

                

    Avanos Medical Inc


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    05350V106


    (CUSIP Number)

    December 30, 2022


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. 05350V106

    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    Dimensional Fund Advisors LP
    30-0447847
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) [ ]
    (b) [X]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware Limited Partnership

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 2,834,753 ** see Note 1 **
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER 2,891,836 ** see Note 1 **
    8. SHARED DISPOSITIVE POWER 0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,891,836 ** see Note 1 **
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.2%
    12. TYPE OF REPORTING PERSON

    IA

    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    


    Item 1.
    (a) Name of Issuer
    Avanos Medical Inc
    (b) Address of Issuer's Principal Executive Offices
    5405 Windward Parkway, Alpharetta, GA 30004
    Item 2.
    (a) Name of Person Filing
    Dimensional Fund Advisors LP
    (b) Address of Principal Business Office or, if None, Residence
    6300 Bee Cave Road, Building One, Austin, TX 78746
    (c) Citizenship
    Delaware Limited Partnership
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    05350V106
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [ ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    2,891,836 ** see Note 1 **
    (b) Percent of Class:
    6.2%
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 2,834,753 ** see Note 1 **
    (ii) shared power to vote or to direct the vote 0
    (iii) sole power to dispose or to direct the disposition of 2,891,836 ** see Note 1 **
    (iv) shared power to dispose or to direct the disposition of 0
    ** Note 1 ** Dimensional Fund Advisors LP, an investment adviser registered under Section 203 of the Investment Advisors Act of 1940, furnishes investment advice to four investment companies registered under the Investment Company Act of 1940, and serves as investment manager or sub-adviser to certain other commingled funds, group trusts and separate accounts (such investment companies, trusts and accounts, collectively referred to as the "Funds"). In certain cases, subsidiaries of Dimensional Fund Advisors LP may act as an adviser or sub-adviser to certain Funds. In its role as investment advisor, sub-adviser and/or manager, Dimensional Fund Advisors LP or its subsidiaries (collectively, "Dimensional") may possess voting and/or investment power over the securities of the Issuer that are owned by the Funds, and may be deemed to be the beneficial owner of the shares of the Issuer held by the Funds. However, all securities reported in this schedule are owned by the Funds. Dimensional disclaims beneficial ownership of such securities. In addition, the filing of this Schedule 13G shall not be construed as an admission that the reporting person or any of its affiliates is the beneficial owner of any securities covered by this Schedule 13G for any other purposes than Section 13(d) of the Securities Exchange Act of 1934.
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    The Funds described in Note 1 above have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the securities held in their respective accounts. To the knowledge of Dimensional, the interest of any one such Fund does not exceed 5% of the class of securities. Dimensional Fund Advisors LP disclaims beneficial ownership of all such securities.
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Not Applicable
    Item 8. Identification and Classification of Members of the Group.

    Not Applicable. This schedule is not being filed pursuant to Rule 13d-1(b)(1)(ii)(J) or Rule 13d-1(d).
    Item 9. Notice of Dissolution of Group.

    Not Applicable
    Item 10. Certification.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dimensional Fund Advisors LP
    By: Dimensional Holdings Inc., General Partner
    By: /s/ Selwyn Notelovitz
    Date: February 14, 2023
    Name: Selwyn Notelovitz
    Title: Global Chief Compliance Officer

    Get the next $AVNS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVNS

    DatePrice TargetRatingAnalyst
    7/25/2023Overweight → Sector Weight
    KeyBanc Capital Markets
    5/22/2023$31.00Buy
    CL King
    2/24/2022$47.00 → $41.00Overweight
    Keybanc
    1/7/2022$37.00 → $36.00Underweight
    Morgan Stanley
    8/4/2021$45.00 → $41.00Underweight
    Morgan Stanley
    8/4/2021$60.00 → $45.00Overweight → Equal-Weight
    Stephens
    8/4/2021$55.00 → $47.00Overweight
    Keybanc
    More analyst ratings

    $AVNS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avanos Medical, Inc. Announces First Quarter 2025 Results

      ALPHARETTA, Ga., May 6, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported first quarter 2025 financial results. "In my first couple of weeks at Avanos, I've noticed that the transformation efforts made around the portfolio, the organizational structure and cost management have positioned us well to accelerate our growth profile," said David Pacitti, Avanos's recently appointed Chief Executive Officer. Pacitti continued, "I really like the energy and strategic focus we have right now, which can be leveraged for more consistent execution, to identify more go-t

      5/6/25 7:00:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical, Inc. to Webcast Conference Call Discussing First Quarter 2025 Financial Results

      ALPHARETTA, Ga., April 28, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) will webcast its conference call discussing financial results and business highlights for the first quarter 2025 on Tuesday, May 6 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day. The conference call will be hosted by Dave Pacitti, chief executive officer, Jason Pickett, interim chief financial officer, Scott Galovan, senior vice president, strategy and corporate development, and Gary Blackford, Avanos board chairman. To instantly jo

      4/28/25 7:47:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Expands Direct Operations for MIC-KEY* Enteral Feeding Products in the UK starting July 2025

      ZAVENTEM, Belgium, April 2, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) a global medical technology company, today announced that it will take direct responsibility for the sales and distribution of its MIC-KEY enteral feeding products in the United Kingdom, effective 25 July 2025. This strategic move reflects Avanos' commitment to prioritizing customer needs, enhancing product availability into the future, and providing a seamless experience for healthcare providers and patients. For the past 29 years, Vygon UK, a leading supplier of surgical and medical devices has

      4/2/25 7:00:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care

    $AVNS
    Leadership Updates

    Live Leadership Updates

    See more
    • Avanos Medical Announces Appointment of David Pacitti as Chief Executive Officer

      ALPHARETTA, Ga., March 17, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS), a leading medical technology company, today announced the appointment of David Pacitti as its new chief executive officer, effective April 14, 2025. Pacitti joins Avanos with a distinguished career in the healthcare sector, most recently serving as president of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers. In this capacity, he played a pivotal role in driving strategic growth and operational excellence while leading the marketing, sales, service, and support

      3/17/25 7:30:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical, Inc. Appoints Indrani Franchini to Board of Directors

      ALPHARETTA, Ga., July 1, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Indrani Franchini has been appointed as a new independent member of the Avanos board of directors. "We are excited to welcome Indrani Franchini to the Avanos board," remarked Gary Blackford, Avanos board chair. "Her experience with a broad range of global companies will be invaluable to Avanos as we pursue our vision of getting patients back to the things that matter." "Avanos is committed to addressing some of today's most important healthcare needs and I am thrilled to join it

      7/1/24 7:00:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical, Inc. Appoints Sig Delgado as Senior Vice President, Integrated Supply Chain

      ALPHARETTA, Ga., May 13, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Sigfrido (Sig) Delgado has been appointed senior vice president, integrated supply chain. In this role, Delgado will lead the teams focused on implementing continuous improvements within the Company's end-to-end supply chain capabilities worldwide. Delgado joins Avanos from Jabil Healthcare, the industry's largest global provider of healthcare manufacturing solutions, where he most recently served as vice president of its global medical technology business. His background includ

      5/13/24 7:15:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care

    $AVNS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Pickett Jason Marc claimed ownership of 40,113 shares (SEC Form 3)

      3 - AVANOS MEDICAL, INC. (0001606498) (Issuer)

      4/29/25 3:45:04 PM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Amendment: New insider Pacitti David claimed ownership of 242,047 shares (SEC Form 3)

      3/A - AVANOS MEDICAL, INC. (0001606498) (Issuer)

      4/24/25 5:00:37 PM ET
      $AVNS
      Industrial Specialties
      Health Care
    • New insider Pacitti David claimed ownership of 242,047 shares (SEC Form 3)

      3 - AVANOS MEDICAL, INC. (0001606498) (Issuer)

      4/24/25 12:08:46 PM ET
      $AVNS
      Industrial Specialties
      Health Care

    $AVNS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Avanos Medical downgraded by KeyBanc Capital Markets

      KeyBanc Capital Markets downgraded Avanos Medical from Overweight to Sector Weight

      7/25/23 6:15:12 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • CL King initiated coverage on Avanos Medical with a new price target

      CL King initiated coverage of Avanos Medical with a rating of Buy and set a new price target of $31.00

      5/22/23 8:52:10 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Keybanc reiterated coverage on Avanos Medical with a new price target

      Keybanc reiterated coverage of Avanos Medical with a rating of Overweight and set a new price target of $41.00 from $47.00 previously

      2/24/22 4:48:01 AM ET
      $AVNS
      Industrial Specialties
      Health Care

    $AVNS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Avanos Medical Inc.

      10-Q - AVANOS MEDICAL, INC. (0001606498) (Filer)

      5/6/25 4:17:36 PM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - AVANOS MEDICAL, INC. (0001606498) (Filer)

      5/6/25 7:07:11 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - AVANOS MEDICAL, INC. (0001606498) (Filer)

      4/30/25 9:47:43 AM ET
      $AVNS
      Industrial Specialties
      Health Care

    $AVNS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Avanos Medical Inc.

      SC 13G - AVANOS MEDICAL, INC. (0001606498) (Subject)

      11/14/24 1:28:34 PM ET
      $AVNS
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Avanos Medical Inc. (Amendment)

      SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)

      2/14/24 11:41:02 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Avanos Medical Inc. (Amendment)

      SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)

      2/13/24 4:58:57 PM ET
      $AVNS
      Industrial Specialties
      Health Care

    $AVNS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Shimer Julie Ann bought $9,925 worth of shares (500 units at $19.85), increasing direct ownership by 1% to 50,090 units (SEC Form 4)

      4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)

      3/11/24 5:15:37 PM ET
      $AVNS
      Industrial Specialties
      Health Care

    $AVNS
    Financials

    Live finance-specific insights

    See more
    • Avanos Medical, Inc. Announces First Quarter 2025 Results

      ALPHARETTA, Ga., May 6, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported first quarter 2025 financial results. "In my first couple of weeks at Avanos, I've noticed that the transformation efforts made around the portfolio, the organizational structure and cost management have positioned us well to accelerate our growth profile," said David Pacitti, Avanos's recently appointed Chief Executive Officer. Pacitti continued, "I really like the energy and strategic focus we have right now, which can be leveraged for more consistent execution, to identify more go-t

      5/6/25 7:00:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical, Inc. to Webcast Conference Call Discussing First Quarter 2025 Financial Results

      ALPHARETTA, Ga., April 28, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) will webcast its conference call discussing financial results and business highlights for the first quarter 2025 on Tuesday, May 6 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day. The conference call will be hosted by Dave Pacitti, chief executive officer, Jason Pickett, interim chief financial officer, Scott Galovan, senior vice president, strategy and corporate development, and Gary Blackford, Avanos board chairman. To instantly jo

      4/28/25 7:47:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2024 Results

      ALPHARETTA, Ga., Feb. 26, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported fourth quarter and full-year 2024 results. "We are pleased with our fourth quarter results, which delivered 5% organic growth and continued execution on each of our transformation initiative priorities," said Michael Greiner, Avanos's interim chief executive officer. Greiner continued, "For the full year, we generated $83 million of free cash flow and $108 million of adjusted EBITDA. We currently have net debt of approximately $20 million. We believe our strong financial position wil

      2/26/25 7:00:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care